KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Current Assets (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Current Assets for 14 consecutive years, with $437.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 5.01% year-over-year to $437.6 million, compared with a TTM value of $437.6 million through Dec 2025, up 5.01%, and an annual FY2025 reading of $437.6 million, up 5.01% over the prior year.
  • Current Assets was $437.6 million for Q4 2025 at Travere Therapeutics, up from $371.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $631.1 million in Q1 2022 and bottomed at $324.7 million in Q3 2024.
  • Average Current Assets over 5 years is $496.5 million, with a median of $534.8 million recorded in 2022.
  • The sharpest move saw Current Assets surged 42.01% in 2021, then crashed 32.44% in 2024.
  • Year by year, Current Assets stood at $582.8 million in 2021, then dropped by 16.54% to $486.4 million in 2022, then increased by 26.79% to $616.8 million in 2023, then tumbled by 32.44% to $416.7 million in 2024, then rose by 5.01% to $437.6 million in 2025.
  • Business Quant data shows Current Assets for TVTX at $437.6 million in Q4 2025, $371.1 million in Q3 2025, and $379.6 million in Q2 2025.